Division of Infectious Diseases, Northwestern University, Chicago, Illinois 60611, USA.
J Infect Dis. 2011 Aug 15;204(4):515-20. doi: 10.1093/infdis/jir353.
Population sequencing was performed for persons identified with persistent low-level viremia in 2 clinical trials. Persistent low-level viremia (defined as plasma HIV-1 RNA level >50 and <1000 copies/mL in at least 2 determinations over a 24-week period, after at least 24 weeks of antiretroviral therapy) was observed in 65 (5.6%) of 1158 patients at risk. New resistance mutations were detected during persistent low-level viremia in 37% of the 54 evaluable cases. The most common mutations were M184I/V (14 cases), K103N (9), and M230L (3). Detection of new mutations was associated with higher HIV-1 RNA levels during persistent low-level viremia.
人群测序在两项临床试验中针对持续低水平病毒血症的患者进行。持续低水平病毒血症（定义为在至少 24 周抗逆转录病毒治疗后至少 24 周的 24 周期间，至少有 2 次测定的血浆 HIV-1 RNA 水平>50 和<1000 拷贝/毫升）在 1158 名高危患者中的 65 名（5.6%）中观察到。在 54 例可评估病例中，有 37%的病例在持续低水平病毒血症期间检测到新的耐药突变。最常见的突变是 M184I/V（14 例）、K103N（9 例）和 M230L（3 例）。在持续低水平病毒血症期间，新突变的检测与 HIV-1 RNA 水平升高相关。
